Although HbA2 is typically expressed at low levels, it is fully functional and improves SCD and β-thal features in animal models, thereby validating the delta globin gene as a potential therapeutic target [6,7]. This evidence concerns the gene HBA2 and Schnyder corneal dystrophy.